SOUTH SAN FRANCISCO, CA, USA I4, 2024 I Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to ...
WATERTOWN, MA, USA I4, 2024 I Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene ...
BOSTON, MA, USA I October 24, 2024 I BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein ...
NORTH CHICAGO, IL, USA and BUDAPEST, Hungary I4, 2024 I AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, ...
CULVER CITY, CA, USA I October 24, 2024 I Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential ...
BERLIN, Germany and BOSTON, MA, USA I4, 2024 I Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart ...
Enables ATX-559 Phase 1 study in solid tumor patients with a focus on BRCA1/2-deficient breast cancer and solid tumors with microsatellite instability (MSI-H) ...
NG-350A will now be studied in combination with chemoradiotherapy in FORTRESS, a multicenter open-label non-randomized Phase 1b trial of patients with locally advanced rectal cancer.
PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET, with the potential to be a ...
New development candidate, NTX-452, a non-covalent WRN inhibitor, demonstrated significant tumor regression and complete responses at low oral doses in ...
SAN FRANCISCO, CA, USA and SINGAPORE I October 23, 2024 I Hummingbird Bioscience, a precision biotherapeutics company discovering and developing ...
BASEL, Switzerland I October 23, 2024 I AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback